000 | 01972 a2200589 4500 | ||
---|---|---|---|
005 | 20250514211429.0 | ||
264 | 0 | _c20050118 | |
008 | 200501s 0 0 eng d | ||
022 | _a0066-4804 | ||
024 | 7 |
_a10.1128/AAC.48.12.4835-4842.2004 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aRamanathan-Girish, Sandhya | |
245 | 0 | 0 |
_aPharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. _h[electronic resource] |
260 |
_bAntimicrobial agents and chemotherapy _cDec 2004 |
||
300 |
_a4835-42 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAmidohydrolases _xantagonists & inhibitors |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 | _aArea Under Curve |
650 | 0 | 4 |
_aCentral Nervous System Diseases _xchemically induced |
650 | 0 | 4 | _aCross-Over Studies |
650 | 0 | 4 | _aDogs |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydroxamic Acids _xadministration & dosage |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred ICR |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Sprague-Dawley |
650 | 0 | 4 | _aSpecies Specificity |
700 | 1 | _aMcColm, Juliet | |
700 | 1 | _aClements, John M | |
700 | 1 | _aTaupin, Phil | |
700 | 1 | _aBarrowcliffe, Sue | |
700 | 1 | _aHevizi, John | |
700 | 1 | _aSafrin, Sharon | |
700 | 1 | _aMoore, Clive | |
700 | 1 | _aPatou, Gary | |
700 | 1 | _aMoser, Heinz | |
700 | 1 | _aGadd, Alison | |
700 | 1 | _aHoch, Ute | |
700 | 1 | _aJiang, Vernon | |
700 | 1 | _aLofland, Denene | |
700 | 1 | _aJohnson, Kirk W | |
773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 48 _gno. 12 _gp. 4835-42 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.48.12.4835-4842.2004 _zAvailable from publisher's website |
999 |
_c15247716 _d15247716 |